Aimmune Therapeutics is developing desensitization treatments to protect people with food allergies from the life-threatening consequences of accidental exposure.
Aimmune Therapeutics’ treatments use standardized, pharmaceutical-grade food allergens and a characterized oral desensitization immunotherapy system (CODIT™). Aimmune Therapeutics recently completed a Phase 2 study of its lead product candidate, AR101, for the treatment of peanut allergy. Peanut allergies are a real and growing problem, with allergies to peanuts having more than quadrupled in the U.S. in the 13 years prior to 2010. According to the Journal of Allergy and Clinical Immunology, more than 2 percent of children age 18 years and younger have a peanut allergy and it is the leading cause of death related to food allergy in the United States.
Foresite Capital has been actively monitoring the food allergy space. In early 2015 we led Aimmune Therapeutics’ $80 million Series B financing. Aimmune Therapeutics met our investment criteria; they have a solid management team with deep industry experience, a transformative product with demonstrated efficacy and strong Phase II Data, and the potential to solve a real-world problem in a large market with a strong unmet medical need. Aimmune Therapeutics is currently preparing to start its Phase 3 study for the treatment of peanut allergy. They are also working on developing treatments for other common food allergies using its standardized, pharmaceutical-grade food allergens and the CODIT™ system. The U.S. Food and Drug Administration has granted AR101 Fast Track designation as part of its program to facilitate and expedite the development and review of drugs designed to treat serious conditions and fill an unmet medical need.